Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFIRM: Risankizumab SC Induction in Crohn's Disease
NCT06063967Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in Crohn's disease (5 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With Crohn's Disease Activity Index Clinical Remission (CDAI < 150) at 12 weeks, Percentage of Participants With Endoscopic Response at 12 weeks and 1 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06063967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063967.